Back to top
more

SESEN BIO, INC. (SESN)

(Delayed Data from NSDQ)

$1.30 USD

1.30
2,172,114

+0.07 (5.69%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.30 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Axsome (AXSM) Hurt by Regulatory Setbacks: Will It Recover?

by Zacks Equity Research

Axsome's (AXSM) extension of the review period for AXS-05 NDA and CRL for AXS-07 NDA hurt prospects. However, recent positive updates on AXS-05 are driving positive sentiments.

Pfizer (PFE) Inks Deal With US Government for COVID Jab Supply

by Zacks Equity Research

Pfizer (PFE) and partner BioNTech (BNTX) enter into an agreement with the government of the United States to supply 105 million doses of its mRNA-based COVID-19 vaccine.

Regeneron (REGN) Eylea sBLA for Extended Regimen Accepted

by Zacks Equity Research

FDA accepts Regeneron's (REGN) application seeking label expansion for Eylea for an extended period in patients with diabetic retinopathy.

Pfizer (PFE) Discloses Autoimmune Drug Deal With Priovant

by Zacks Equity Research

Pfizer (PFE) announces the name of the new company that it formed with its partner, Roivant Sciences (ROIV), to develop and market its dual TYK2/JAK1 inhibitor.

Gilead's (GILD) Yescarta Gets EC Nod for Follicular Lymphoma

by Zacks Equity Research

Gilead's (GILD) cell therapy, Yescarta, gets approval in Europe for a third indication- adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.

4 Reasons Why Investors Should Buy Merck (MRK) Stock Now

by Zacks Equity Research

Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and a solid pipeline are some key reasons to own Merck's (MRK) stock.

AstraZeneca (AZN) Drugs Get CHMP Recommendation for Breast Cancer

by Zacks Equity Research

The EMA's Committee for Medicinal Products for Human Use recommends granting marketing approval to AstraZeneca's (AZN) cancer drugs, Enhertu and Lynparza, for treating certain patients with breast cancer.

Kezar (KZR) Doubles on Promising Kidney Disorder Study Data

by Zacks Equity Research

Shares of Kezar (KZR) surge more than 100% during after-hour trading on Jun 27, following a promising data readout from a mid-stage study evaluating zetomipzomib in patients with active lupus nephritis.

Sanofi (SNY) Wins Nod for Nexviadyme & Xenpozyme in Europe

by Zacks Equity Research

Sanofi's (SNY) Nexviadyme is approved for the treatment of both late-onset Pompe disease and infantile-onset Pompe disease. Xenpozyme is approved for non-Central Nervous System (CNS) manifestations of acid sphingomyelinase deficiency (ASMD) disease.

    Axsome (AXSM) Surges Following FDA Label Proposal for AXS-05

    by Zacks Equity Research

    Axsome (AXSM) receives proposed labeling from the FDA for its under-review depression drug candidate, AXS-05, implying a potential approval soon. Shares surge more than 50%.

    Gilead (GILD) Resubmits NDA for HIV Inhibitor to the FDA

    by Zacks Equity Research

    Gilead (GILD) announces the resubmission of the NDA for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in the United States.

    Epizyme (EPZM) Stock Surges on Acquisition Offer From Ipsen

    by Zacks Equity Research

    Ipsen, through its wholly-owned subsidiary, is set to acquire Epizyme (EPZM) for $1.45 per share, in cash, along with a contingent value right of $1 per share. The transaction is likely to close by third-quarter 2022.

    Emergent's (EBS) Anthrax Vaccine BLA Gets FDA Acceptance

    by Zacks Equity Research

    The FDA accepts Emergent's (EBS) BLA seeking approval for its new anthrax vaccine, AV7909. A decision is expected in April next year.

    Merck (MRK) Keytruda Gets Europe Nod for Expanded Melanoma Use

    by Zacks Equity Research

    European Commission approves Merck's (MRK) Keytruda as an adjuvant treatment for adults and adolescent patients with stage IIB or IIC melanoma and who have undergone complete resection.

    F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm

    by Zacks Equity Research

    Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.

    Sarepta (SRPT) Down on Clinical Hold on DMD Candidate SRP-5051

    by Zacks Equity Research

    The FDA places Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, on clinical hold, following a report of hypomagnesemia in the ongoing phase II MOMENTUM study.

    Merck's (MRK) Pneumococcal Vaccine Gets FDA Nod for Kids

    by Zacks Equity Research

    Merck's (MRK) Vaxneuvance vaccine includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.

    Acer Therapeutics (ACER) Gets CRL for Urea Cycle Disorders Drug

    by Zacks Equity Research

    Acer Therapeutics' (ACER) new drug application for ACER-001 to treat urea cycle disorders faces rejection from the FDA. Share price falls 21% following the announcement.

      Celldex (CLDX) Initiates Phase II Chronic Skin Disorder Study

      by Zacks Equity Research

      Celldex (CLDX) initiates dosing in a mid-stage study designed to evaluate its antibody candidate, barzolvolimab, for treating patients with chronic spontaneous urticaria.

      J&J's (JNJ) Stock Outperforms Industry YTD: Here's Why

      by Zacks Equity Research

      J&J's (JNJ) Pharma unit is performing above market levels. Sales in the Consumer unit are being hurt by external supply constraints. J&J focuses on growing the MedTech segment through new products.

      Pfizer (PFE) to Buy 8.1% Stake in Lyme Disease Vaccine Partner

      by Zacks Equity Research

      Pfizer (PFE) is set to acquire 8.1% stake in Valneva's stock. Valneva will use the cash from this investment to support its phase III study for VLA15.

      AbbVie's (ABBV) Skyrizi Gets FDA Nod for Crohn's Disease

      by Zacks Equity Research

      The FDA approval of AbbVie's (ABBV) Skyrizi for moderately to severely active Crohn's disease was supported by data from two phase III induction studies - ADVANCE, MOTIVATE, and one maintenance study - FORTIFY.

      ObsEva's (OBSV) Yselty Gets EU Nod to Treat Uterine Fibroids

      by Zacks Equity Research

      ObsEva's (OBSV) Yselty receives its first marketing approval in the European Union for the treatment of uterine fibroids in adult women. Shares were up 11% in pre-market trading following the news.

      Rhythm Pharma (RYTM) Down on Mixed Imcivree Regulatory Updates

      by Zacks Equity Research

      The FDA approves label expansion of Rhythm Pharma's (RYTM) Imcivree to include Bardet-Biedl Syndrome patients. However, the FDA provides CRL for label expansion of the drug in Alstrom syndrome.

      Clovis (CLVS) Up 19.4% on Upbeat Data From Solid Tumor Study

      by Zacks Equity Research

      Clovis Oncology (CLVS) reports favorable data from a study, which supports the potential clinical utility of FAP-2286, its targeted radiotherapy candidate, as a treatment for advanced solid tumors.